Publications: Full papers
Lim YY, Jaeger J, Harrington K, Ashwood T, Ellis KA,
Stöffler A, Szoeke C, Lachovitzki R, Martins RN, Villemagne VL, Bush A, Masters
CL, Rowe CC, Ames D, Darby D, and Maruff P. Three-Month Stability of the CogState Brief Battery
in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease:
Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change
Substudy (AIBL-ROCS). Arch Clin
Neuropsychol 3-4-2013.
Gerlach M, Maetzler W, Broich K, Hampel H, Rems L,
Reum T, Riederer P, Stöffler A, Streffer J, and Berg D. Biomarker candidates of neurodegeneration in
Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm 2012; 119(1):
39-52.
Winblad B, Jones RW, Wirth Y, Stöffler A, and Möbius
HJ. Memantine in moderate to
severe Alzheimer’s disease (AD): a meta-analysis of randomised clinical trials.
Dementia and Geriatric Cogn Dis 2007;24:20-27.
Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves
memory by restoration of homeostasis in the glutamatergic system - too little
activation is bad, too much is even worse. Neuropharmacology
2007; 53: 699-723.
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S,
and Möbius HJ. A 24-week open-label extension
study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006;63(1):49-54.
Möbius HJ, Stöffler A, Graham SM. Memantine hydrochloride: pharmacological and
clinical profile. Drugs Today
2004;40(8):685-95.
Möbius HJ and Stöffler A. Memantine in vascular dementia. International Psychogeriatrics
2003;15 (Suppl 1):207-13.
Wimo A, Winblad B, Stöffler A, Wirth Y, and Möbius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe
Alzheimer's disease. Pharmacoeconomics 2003;21(5):327-40.
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S,
and Möbius HJ. Memantine in
moderate-to-severe Alzheimer's disease. N
Engl J Med 2003;348(14):1333-41.
Winblad B, Möbius HJ, and Stöffler A. Glutamate receptors as a target for AD - are
clinical results supporting the hope? J
Neural Transm 2002;62(Suppl.):217-25.
Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, and
Forette F. Efficacy and safety of
memantine in patients with mild to moderate vascular dementia; a randomized,
placebo-controlled trial (MMM300). Stroke 2002;331834-9.
Möbius HJ and Stöffler A. New approaches to clinical trials in vascular
dementia: Memantine in small vessel disease. Cerebrovasc Dis 2002;13(Suppl. 2):61-6.
Wilcock G, Stöffler A, and Möbius HJ. A double-blind, placebo-controlled multicenter study
of memantine in mild to moderate vascular dementia (the MMM500 trial). International Clinical Psychopharmacology 2002;17(6):297-305.
Danysz W, Parsons CG, Möbius HJ, Stöffler A, and Quack
G. Neuroprotective and symptomatological
action of memantine relevant for Alzheimer's disease - a unified hypothesis on
the mechanism of action. Neurotoxicity
Research 2000;2(2-3):85-98.
Stöffler A, Baas H, and Fischer
PA. [Polymorphonuclear leukocyte
elastase in the cerebrospinal fluid in the diagnosis of acute inflammatory
central nervous system diseases]. Nervenarzt 1989;60(7):420-4.
Becker H, Körner P, and Stöffler A. Psychodynamics and therapeutic aspects of anorexia
nervosa. A study of family dynamics and prognosis. Psychother.Psychosom.
1981;36(1):8-16.
Book chapters and selected abstracts
Becker H, Körner P, and Stöffler A. Psychodynamics and therapeutic aspects of anorexia nervosa. The 5th World Congress of the Int College of Psychosomatic Medicine, Jerusalem 1979.
Danysz W, Möbius H-J, Parsons CG, Quack G, Wenk GL, and Stöffler A. Memantine provides neuroprotection in animal models at therapeutically relevant doses. Neurobiol Aging 2000; 21[1S]:S242.
Danysz W, Parsons CG, Möbius HJ, Stöffler A, and Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer´s disease - an unified hypothesis on the mechanism of action. Palomo, T., Benninger, R., and Archer, T. Strategies for Studying Brain Disorders 5: Neurodegenerative Brain Disorders. 2000;485-499. Madrid , Fundación Cerebro y Mente.
Ferris SH, Sinaiko EA, Faiz S, Monteiro IM, Reisberg B, Windscheif U, and Stöffler A. Effects of a rater training program on the clinician interview based impression of change (CIBIC-plus). Neurobiol Aging 2000; 21(1S):S27.
Möbius HJ and Stöffler A. NMDA antagonists in the treatment of severe dementia. European Neuropsychopharmacology 2001; 11[Suppl. 3]:S161.
Möbius HJ, Sahin K, and Stöffler A. Einfluss des Schweregrades der Demenz auf die Verbesserung der Kognition durch Memantine bei vaskulärer Demenz. Vellas, B. and Fitten, L. J. Demenz vom Alzheimertyp - Forschung und Praxis. 2001;37-45. New York , Springer.
Möbius HJ and Stöffler A. Long-term treatment with memantine in advanced AD. European Neuropsychopharmacology 2002; 12[Suppl. 3]:S135.
Möbius HJ, Sahin K, and Stöffler A. Severity Staging and the Magnitude of Cognitive Benefit by Memantine Treatment in Vascular Dementia. Vellas, B., Winblad, B., Grundman, M., Fitten, L. J., Feldman, H., and Giacobini, E. Research and Practice in Alzheimer´s Disease. 2002; 6:354-361. Paris, Serdi Publisher.
Parsons CG, Stöffler A, and Winblad B. Dementia. Lodge, D., Danysz, W., and Parsons, C. G. Ionotropic Glutamate Receptors as Therapeutic Targets. 2002;[8]:229-262. Johnson City (TN), F.P. Graham Publishing Co.
Reisberg B, Windscheif U, Ferris SH, Hingorani VH, Stöffler A, and Möbius H-J. Memantine in moderately severe to severe Alzheimer's disease (AD): results of a placebo-controlled 6-month trial. Neurobiol Aging 2000; 21[1S]:S275.
Reisberg B, Ferris SH, Möbius HJ, Stöffler A, Schmitt F, and Doody RS. Long-term treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderately severe to severe Alzheimer's disease. Neurobiol Aging 2002; 23[1S]:S555.
Reisberg B, Stoeffler A, Ferris S, Schmitt F, Doody RS, and Moebius H-J. A placebo-controlled study of memantine in advanced Alzheimer's disease. American Journal of Geriatric Psychiatry 2002; 10[2 Supp. [1]]:90.
Sahin K, Stöffler A, Furtuna P, Rosenwald D, and Möbius H-J. Dementia severity and the magnitude of cognitive benefit by memantine treatment. A subgroups analysis of two placebo-controlled clinical trials in vascular dementia. Neurobiol Aging 2000; 21[1S]:S168.
Schmidt R, Ropele S, Ebenbauer
N, Windisch M, Stöffler A, and Fazekas F.
Effects of memantine on brain volume, glucose metabolism and cognition in
Alzheimer's disease patients: a neuroimaging study. Alzheimer's & Dementia 2008; 4[4 (Suppl.
2)]:T389-T390
Stöffler A, Ferris SH, Wirth Y, and Reisberg B. Responders to memantine treatment in moderate to severe Alzheimer's Disease. [Abstract] Neurobiol Aging 2004;25:(Suppl.2)S212
Wilcock G, Stöffler A, Sahin K, and Möbius H-J. Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. European Neuropsychopharmacology 2000; 10[Suppl. 3]:S360.
Wimo A, Winblad B, Stöffler A, Wirth Y, and Möbius HJ. Effects of long-term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28-week, randomized, double-blind, placebo-controlled study. Neurobiol Aging 2002; 23[1S]:S44.
Wirth Y, Doody RS, Schmitt FA, Möbius HJ, and Stöffler A. Memantine treatment is beneficial for functional capacities of patients with moderate to severe Alzheimer's disease. [Abstract] Int J Neuropsychopharmacol 2004;7:(Suppl.1)S207
